Multiple companies have made offers for Aurora's business this year, but Tilray hasn't shown any interest.
Analyst rates Curaleaf (CURLF) a Buy on long-term potential and strong finances. The stock price has been down over the last year.
Announced that it has received competition law clearances in Germany and Canada for its proposed acquisition ...
Organigram is valuing Aurora Cannabis more highly than Curleaf, but that doesn't mean it's the best option for shareholders in the long run.
Aurora Cannabis faces domestic headwinds, but Europe growth and a stronger Organigram bid may offer upside.
Key Takeaways; Cannabis Sector Organigram to Acquire Aurora Cannabis in C$561 Million Deal, Creating Global Cannabis Powerhouse Canopy Growth Posted 22% Revenue Growth as International Cannabis Sales Surged 141% Key Takeaways; Psychedelic Sector Bright Minds Biosciences Received Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Trial Optimi Health Established Australian Subsidiary to Expand Psychedelic […]
Aurora Cannabis (ACB) delivered earnings and revenue surprises of +200.00% and +17.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
Edmonton-based producer spent past several months trying to fend off a hostile takeover attempt from Curaleaf Holdings
Organigram Global agreed to buy Aurora Cannabis, topping a hostile bid from U.S. weed chain Curaleaf Holdings.
Organigram Global (OGI.TO, OGI) and Aurora Cannabis (ACB.TO, ACB) entered into an arrangement agreem
Aurora Cannabis (ACB) stock rises as Organigram OGI) agrees to acquire the company in a C$561M cash-stock deal, ending Curaleaf’s (CURLF) hostile bid. Read more here.
A look at some small-cap stocks making news - or about to.
Aurora Cannabis Inc., the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time| 6:00 a.m. Mountain Time to discuss its financial results for the second quarter 2027. Q2 FY27 Financial Results Call, November 12, 2026.
Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today issued the following statement in response to the Alberta Securities Commission's ruling regarding Aurora Cannabis Inc.'s ("Aurora") at-the-market ("ATM") program.
Oil prices holding above $110 have put energy costs back in the spotlight, which can pressure many parts of the economy while keeping demand steady for essential services like Canadian healthcare. Investors looking for businesses with resilient demand are again paying attention to leading healthcare providers, drug makers, and equipment specialists with solid finances. This article highlights three of the strongest Canadian healthcare stocks from that group. The three healthcare stocks in...
Curaleaf Holding first approached Aurora about a friendly merger, and after it was rejected, launched a hostile bid.
Curaleaf condemns Aurora Cannabis for rejecting its enhanced proposal, accusing the board of obstructing engagement and fair value.
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s ("Aurora") Notice of Change to its directors' circular, dated October 14, 2026, in which Aurora's Board again recommended that shareholders reject Curaleaf's enhanced proposal.
Reconfirms that the Board of Directors, on the unanimous recommendation of a special committee of independent ...
This is the newest page. Registered accounts read further back.